Licensing and oversight
Ask which local rules apply, what oversight exists, and how the centre describes its legal operating basis.
A practical comparison framework
Centre Comparison
A clear set of questions for comparing individual ibogaine therapy centres—without assuming that a polished setting, a confident answer, or a stated protocol makes care safe.
Ask for specifics
Compare like with like
Keep uncertainty visible
The comparison fields
Compare the operational details, not the promise.
Ibogaine is medically hazardous and its regulatory status differs by jurisdiction. A useful comparison starts with the centre’s concrete safeguards, its willingness to explain limits, and the questions it can answer consistently.
Medical presence and response capacity
Ask who is on site during dosing, what resuscitation equipment is available, and how an emergency transfer would work.
Drug sourcing and testing
Ask what is known about sourcing, identity, handling, and any purity or contaminant testing before use.
Monitoring protocol
Ask what monitoring is used, who interprets it, and how findings change decisions during the stay.
Aftercare and escalation
Ask what support is planned after departure, how warning signs are handled, and where responsibility ends.
Outcomes and cultural context
Ask what outcomes are tracked, what is shared, and how a biomedical setting differs from ceremonial or other cultural contexts.
Stage by stage
Trace the whole pathway before comparing the middle.
Centres can sound similar when discussing a single session. Compare the full sequence: selection, preparation, observation, discharge, and the plan for what follows.
Before acceptance
Ask how health history, medicines, substance use, mental health, and contraindications are assessed before a person is accepted.
Before dosing
Ask what preparation is required, what baseline checks are performed, and what would postpone or stop the process.
During observation
Ask about staffing, monitoring, documentation, communication with the participant, and the threshold for emergency action.
After discharge
Ask how follow-up is structured, what records a participant receives, and what the centre advises if complications or relapse concerns emerge later.
Annotated checklist
What to record for every centre.
-
✓
Ask for the screening sequence.
This matters because medication interactions, cardiac history, and other risk factors cannot be responsibly reduced to a quick eligibility claim.
-
✓
Ask who can respond to a medical emergency.
This clarifies whether emergency capability is present, how it is activated, and whether the answer describes a real process rather than a general reassurance.
-
✓
Ask how the substance is identified and handled.
Questions about sourcing, batch records, testing, storage, and dose decisions make uncertainty around the material itself more visible.
-
✓
Ask what is monitored and documented.
A centre should be able to explain the purpose of its monitoring, who reviews findings, and how monitoring affects a decision to continue or escalate care.
-
✓
Ask what is known after participants leave.
Follow-up plans and transparent outcome records matter because a short stay cannot answer every question about later benefit, harm, or support needs.
Suggested questions
Use direct questions. Keep the answers.
- Which licensing or oversight arrangements apply to this setting?
- Who is on site while ibogaine is administered, and what can they do in an emergency?
- What resuscitation equipment is immediately available, and when was its process last reviewed?
- How are sourcing, identity, and purity or contaminant testing documented?
- What monitoring occurs before, during, and after administration—and who interprets it?
- What would make the centre postpone, stop, or escalate care?
- What aftercare is planned, and what support is available if concerns arise after departure?
- What outcomes, adverse events, or follow-up information are collected and shared?
- How does the centre distinguish its setting from ceremonial, cultural, or research contexts?
Descriptions of ibogaine’s background and use can vary widely by setting; comparison is more informative when a centre clearly explains what it does and does not provide.
A measured next step
A checklist supports questions; it does not settle risk.
Use the same notes for each centre, retain written answers where possible, and keep claims about outcomes separate from evidence. The risk and screening questions can help focus comparison on the issues that may change whether a setting is appropriate to consider at all. For treatment standards in substance-use care more broadly, SAMHSA’s national help resources provide an established reference point outside any individual centre’s marketing.